Welcome to our dedicated page for Clover Health Investments SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating Medicare Advantage metrics, Star Ratings disclosures, or executive stock sales in Clover Health Investments Corp. (NASDAQ: CLOV) filings can feel like navigating a clinical trial protocol. Each 10-K spans hundreds of pages of risk-adjustment tables and value-based care jargon, and new 8-K announcements on CMS guidance appear without warning. Stock Titan solves that problem by pairing real-time EDGAR feeds with AI that translates dense language into plain English, so understanding Clover Health SEC documents with AI becomes routine.
Need the latest Clover Health quarterly earnings report 10-Q filing or curious about Clover Health insider trading Form 4 transactions? Our platform flags material changes—medical loss ratio shifts, membership growth, technology-licensing revenue—in seconds. AI-powered summaries underline where Clover Assistant costs are booked, while redlining highlights any section that affects revenue recognition. You can even set alerts for Clover Health Form 4 insider transactions real-time, keeping track of executive stock transactions Form 4 before the market digests them.
Use the dashboard to move from broad disclosure to actionable insight:
- Clover Health annual report 10-K simplified—spot Star Rating impacts, risk factors, and segment data
- Clover Health proxy statement executive compensation—compare incentive metrics tied to MA growth
- Clover Health 8-K material events explained—follow CMS rate notices or provider network changes
- Clover Health earnings report filing analysis—AI charts quarter-over-quarter medical cost trends
Whether you’re screening for Clover Health SEC filings explained simply or validating a thesis on value-based care adoption, Stock Titan delivers comprehensive coverage, expert context and the speed professional investors expect.
Director Tracy Fitzsimmons filed a Form 4 for Shenandoah Telecommunications (SHEN) covering an 8 Aug 2025 transaction. Fitzsimmons received 70.9584 common shares in lieu of director fees at a reference price of $14.69. Post-transaction direct holdings rise to 44,638.5757 shares. No derivative securities were involved. The filing reflects routine board compensation rather than market-driven buying; monetary value is roughly $1,042, immaterial relative to SHEN’s market cap. No dispositions, option exercises or 10b5-1 plan indications were disclosed.
Form 4 � Kinder Morgan, Inc. (KMI) discloses that Vice President & General Counsel Catherine C. James settled 51,994 restricted stock units (RSUs) into Class P common shares on 31 Jul 2025 (code M). To satisfy tax-withholding requirements, the issuer retained 19,951 shares at the $28.06 closing price (code F), leaving a net 32,043-share increase in the insider’s direct ownership at zero cash cost.
Post-transaction, James directly owns 142,604 shares and indirectly holds 361 shares (75 via spouse, 286 via 401(k)). All reported RSUs are now fully vested; no derivative securities remain outstanding.
The filing reflects routine equity-compensation settlement rather than discretionary buying or selling, carrying neutral market implications but signalling continued executive equity alignment.
Form 4 highlights: On 31 Jul 2025, Clover Health (CLOV) officer Conrad Wai had 27,930 Class A shares withheld at $2.89 (Code F) to satisfy tax on the vesting of 12.5 % of an RSU grant dated 31 Oct 2023. The withheld amount equals roughly 1.7 % of his direct stake.
Post-transaction holdings: Wai still controls 1,671,837 shares directly and 1,403,701 shares indirectly through a family trust—about 3.08 M shares in total—so economic exposure remains virtually unchanged.
Investor takeaway: Because the disposition is automatic, not an open-market trade, it conveys no bearish signal. Remaining RSUs continue to vest quarterly until 31 Oct 2025, maintaining long-term alignment between the executive and shareholders. Market impact is expected to be minimal.
Seaport Entertainment Group Inc. (SEG) � Form 4 filing
CFO Matthew M. Partridge reported an automatic share withholding on 01 Aug 2025 related to the vesting of restricted stock issued under the 2024 Equity Incentive Plan. The issuer withheld 5,429 common shares (Transaction Code “F�) at a reference price of $22.48 to satisfy payroll-tax obligations; no open-market sale or cash proceeds occurred.
Following the tax withholding, Partridge’s direct ownership totals 82,079 SEG shares. No derivative positions were reported or altered. Because Code F denotes a compulsory, non-discretionary transaction, the event is generally viewed as administratively neutral and does not signal a change in executive sentiment or company fundamentals.
Form 144 filing: An unidentified Kinder Morgan, Inc. (KMI) insider has notified the SEC of an intent to sell up to 40,000 common shares on or about 08/04/2025 through Morgan Stanley Smith Barney. At the implied price in the notice, the block is worth approximately $1.124 million.
The shares originate from restricted stock units that vested on 07/31/2025. With roughly 2.222 billion KMI shares outstanding, the proposed sale equals less than 0.002% of total float—an amount that is not expected to influence liquidity, control, or market pricing.
No other sales were reported during the previous three-month period. The filer affirms there is no non-public adverse information, and the submission fulfills Rule 144’s advance-notice requirement. The document conveys no changes to Kinder Morgan’s operations, financial guidance, or capital structure; it is strictly a procedural disclosure of a routine, small-scale insider sale.
Natuzzi S.p.A. (NYSE: NTZ) filed a Form 6-K to announce that CEO and executive director Antonio Achille resigned effective 30 July 2025 after four years in the role. The Board has granted interim CEO authority to Executive Chairman Pasquale Natuzzi while a search for a permanent successor is conducted. No financial figures or changes to strategic guidance were disclosed in this filing.
The resignation removes the architect of the company’s recent transformation program, introducing near-term leadership uncertainty at a critical point in Natuzzi’s turnaround efforts. However, continuity is partially preserved because the founder-chairman will steer operations temporarily. Investors� focus will shift to the timing, profile and mandate of the eventual replacement and whether current strategic initiatives remain intact.
The Vanguard Group filed Amendment No. 10 to Schedule 13G on 29 Jul 2025, disclosing its passive ownership of Apple Inc. (AAPL) as of 30 Jun 2025.
Vanguard beneficially owns 1,415,826,462 Apple common shares, representing 9.47 % of the outstanding class. It reports 0 shares with sole voting power and 19,800,347 shares with shared voting power, while holding sole dispositive power over 1,343,278,627 shares and shared dispositive power over 72,547,835 shares.
The firm qualifies as an investment adviser under Rule 13d-1(b)(1)(ii)(E) and certifies the holdings were acquired in the ordinary course of business, with no intent to influence Apple’s control. No additional material transactions or strategic intentions are noted.
On 24 Jul 2025 Kestra Medical Technologies (KMTS) director Raymond W. Cohen filed Form 4 disclosing the automatic conversion and acquisition of 12,994 restricted common shares. The shares arose from previously granted Class A units of West Affum Holdings that converted in conjunction with the company’s IPO; therefore, no cash consideration was paid (transaction code “A�). After the event, Cohen’s beneficial ownership stands at 12,994 KMTS shares held directly.
The award vests in three tranches: 4,331 shares vested immediately on 24 Jul 2025; an additional 4,331 will vest on 24 Jul 2026; and the remaining 4,332 will vest on 24 Jul 2027. The filing shows no open-market purchases, sales, option activity, or derivative positions, and it contains no financial performance metrics.
While the transaction modestly increases insider alignment, the share amount is relatively small and is unlikely to be market-moving by itself.